Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib

In chronic-phase chronic myeloid leukemia (CP-CML) patients treated with frontline imatinib, failure to achieve early molecular response (EMR; EMR failure: BCR-ABL1 >10% on the international scale at 3 months) is predictive of inferior outcomes. Identifying patients at high-risk of EMR failure at...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood Adv
Главные авторы: Kok, Chung H., Yeung, David T., Lu, Liu, Watkins, Dale B., Leclercq, Tamara M., Dang, Phuong, Saunders, Verity A., Reynolds, John, White, Deborah L., Hughes, Timothy P.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2019
Предметы:
Myeloid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538873/
https://ncbi.nlm.nih.gov/pubmed/31126916
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000195
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы